Patients' choice of treatment in stage D prostate cancer

Barrie R. Cassileth, Edward James Seidmon, Mark S. Soloway, Howard I. Hait, Nicholas J. Vogelzang, Gerard T. Kennealey, Paul S. Schellhammer

Research output: Contribution to journalArticle

177 Citations (Scopus)

Abstract

Given the current preference of many patients for an active role in decision-making regarding their care, the feasibility of patients making their own treatment choices was investigated, and the reasons for their selections were studied. Subjects comprised previously untreated Stage D prostate cancer patients for whom hormonal therapy was indicated. Thirteen institutions entered 159 patients into the study. After discussing treatment choices with their physicians, the patients took home a two-page letter explaining two options: surgical castration and therapy with Zoladex (goserelin acetate), a depot luteinizing hormone-releasing hormone (LHRH) analogue injected subcutaneously every twenty-eight days. Patients were encouraged to discuss the treatment choices with their families. After selecting a treatment approach, patients completed a "decision questionnaire" and then treatment was initiated. Of the 147 patients who completed baseline questionnaires, 78 percent selected Zoladex and 22 percent selected orchiectomy. The primary reason for selecting Zoladex included avoidance of surgery (36%), success of treatment (18%), convenience of the drug (10%), and physician's advice (10%). Patients chose surgery primarily because of convenience (32 %) and success of treatment (29%). Three months later, patients and their wives completed another questionnaire, which assessed their satisfaction with their treatment choices. Ninety-three percent of patients and 91 percent of patients' wives indicated that they would select the same treatment again.

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalUrology
Volume33
Issue number5 SUPPL.
DOIs
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Goserelin
Therapeutics
Spouses
Physicians
Orchiectomy
Patient Preference
Castration
Gonadotropin-Releasing Hormone
Decision Making
Patient Care
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Urology

Cite this

Cassileth, B. R., Seidmon, E. J., Soloway, M. S., Hait, H. I., Vogelzang, N. J., Kennealey, G. T., & Schellhammer, P. S. (1989). Patients' choice of treatment in stage D prostate cancer. Urology, 33(5 SUPPL.), 57-62. https://doi.org/10.1016/0090-4295(89)90108-8

Patients' choice of treatment in stage D prostate cancer. / Cassileth, Barrie R.; Seidmon, Edward James; Soloway, Mark S.; Hait, Howard I.; Vogelzang, Nicholas J.; Kennealey, Gerard T.; Schellhammer, Paul S.

In: Urology, Vol. 33, No. 5 SUPPL., 01.01.1989, p. 57-62.

Research output: Contribution to journalArticle

Cassileth, BR, Seidmon, EJ, Soloway, MS, Hait, HI, Vogelzang, NJ, Kennealey, GT & Schellhammer, PS 1989, 'Patients' choice of treatment in stage D prostate cancer', Urology, vol. 33, no. 5 SUPPL., pp. 57-62. https://doi.org/10.1016/0090-4295(89)90108-8
Cassileth BR, Seidmon EJ, Soloway MS, Hait HI, Vogelzang NJ, Kennealey GT et al. Patients' choice of treatment in stage D prostate cancer. Urology. 1989 Jan 1;33(5 SUPPL.):57-62. https://doi.org/10.1016/0090-4295(89)90108-8
Cassileth, Barrie R. ; Seidmon, Edward James ; Soloway, Mark S. ; Hait, Howard I. ; Vogelzang, Nicholas J. ; Kennealey, Gerard T. ; Schellhammer, Paul S. / Patients' choice of treatment in stage D prostate cancer. In: Urology. 1989 ; Vol. 33, No. 5 SUPPL. pp. 57-62.
@article{c004eca234bf491e8ded118152b63a34,
title = "Patients' choice of treatment in stage D prostate cancer",
abstract = "Given the current preference of many patients for an active role in decision-making regarding their care, the feasibility of patients making their own treatment choices was investigated, and the reasons for their selections were studied. Subjects comprised previously untreated Stage D prostate cancer patients for whom hormonal therapy was indicated. Thirteen institutions entered 159 patients into the study. After discussing treatment choices with their physicians, the patients took home a two-page letter explaining two options: surgical castration and therapy with Zoladex (goserelin acetate), a depot luteinizing hormone-releasing hormone (LHRH) analogue injected subcutaneously every twenty-eight days. Patients were encouraged to discuss the treatment choices with their families. After selecting a treatment approach, patients completed a {"}decision questionnaire{"} and then treatment was initiated. Of the 147 patients who completed baseline questionnaires, 78 percent selected Zoladex and 22 percent selected orchiectomy. The primary reason for selecting Zoladex included avoidance of surgery (36{\%}), success of treatment (18{\%}), convenience of the drug (10{\%}), and physician's advice (10{\%}). Patients chose surgery primarily because of convenience (32 {\%}) and success of treatment (29{\%}). Three months later, patients and their wives completed another questionnaire, which assessed their satisfaction with their treatment choices. Ninety-three percent of patients and 91 percent of patients' wives indicated that they would select the same treatment again.",
author = "Cassileth, {Barrie R.} and Seidmon, {Edward James} and Soloway, {Mark S.} and Hait, {Howard I.} and Vogelzang, {Nicholas J.} and Kennealey, {Gerard T.} and Schellhammer, {Paul S.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1016/0090-4295(89)90108-8",
language = "English",
volume = "33",
pages = "57--62",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Patients' choice of treatment in stage D prostate cancer

AU - Cassileth, Barrie R.

AU - Seidmon, Edward James

AU - Soloway, Mark S.

AU - Hait, Howard I.

AU - Vogelzang, Nicholas J.

AU - Kennealey, Gerard T.

AU - Schellhammer, Paul S.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Given the current preference of many patients for an active role in decision-making regarding their care, the feasibility of patients making their own treatment choices was investigated, and the reasons for their selections were studied. Subjects comprised previously untreated Stage D prostate cancer patients for whom hormonal therapy was indicated. Thirteen institutions entered 159 patients into the study. After discussing treatment choices with their physicians, the patients took home a two-page letter explaining two options: surgical castration and therapy with Zoladex (goserelin acetate), a depot luteinizing hormone-releasing hormone (LHRH) analogue injected subcutaneously every twenty-eight days. Patients were encouraged to discuss the treatment choices with their families. After selecting a treatment approach, patients completed a "decision questionnaire" and then treatment was initiated. Of the 147 patients who completed baseline questionnaires, 78 percent selected Zoladex and 22 percent selected orchiectomy. The primary reason for selecting Zoladex included avoidance of surgery (36%), success of treatment (18%), convenience of the drug (10%), and physician's advice (10%). Patients chose surgery primarily because of convenience (32 %) and success of treatment (29%). Three months later, patients and their wives completed another questionnaire, which assessed their satisfaction with their treatment choices. Ninety-three percent of patients and 91 percent of patients' wives indicated that they would select the same treatment again.

AB - Given the current preference of many patients for an active role in decision-making regarding their care, the feasibility of patients making their own treatment choices was investigated, and the reasons for their selections were studied. Subjects comprised previously untreated Stage D prostate cancer patients for whom hormonal therapy was indicated. Thirteen institutions entered 159 patients into the study. After discussing treatment choices with their physicians, the patients took home a two-page letter explaining two options: surgical castration and therapy with Zoladex (goserelin acetate), a depot luteinizing hormone-releasing hormone (LHRH) analogue injected subcutaneously every twenty-eight days. Patients were encouraged to discuss the treatment choices with their families. After selecting a treatment approach, patients completed a "decision questionnaire" and then treatment was initiated. Of the 147 patients who completed baseline questionnaires, 78 percent selected Zoladex and 22 percent selected orchiectomy. The primary reason for selecting Zoladex included avoidance of surgery (36%), success of treatment (18%), convenience of the drug (10%), and physician's advice (10%). Patients chose surgery primarily because of convenience (32 %) and success of treatment (29%). Three months later, patients and their wives completed another questionnaire, which assessed their satisfaction with their treatment choices. Ninety-three percent of patients and 91 percent of patients' wives indicated that they would select the same treatment again.

UR - http://www.scopus.com/inward/record.url?scp=0024555272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024555272&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(89)90108-8

DO - 10.1016/0090-4295(89)90108-8

M3 - Article

VL - 33

SP - 57

EP - 62

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5 SUPPL.

ER -